About vincerx pharma - VINC
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed M. Hamdy, Raquel E. Izumi, Tom C. Thomas, Soo In Hwang and John C. Byrd on December 19, 2018 and is headquartered in Palo Alto, CA.
VINC At a Glance
Vincerx Pharma, Inc.
1825 South Grant Street
San Mateo, California 94402
| Phone | 1-650-800-6676 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -30,074,000.00 | |
| Sector | Health Technology | Employees | 13 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
VINC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 4.321 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.162 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
VINC Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,313,384.615 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
VINC Liquidity
| Current Ratio | 1.214 |
| Quick Ratio | 1.214 |
| Cash Ratio | 0.959 |
VINC Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -229.38 |
| Return on Equity | -431.292 |
| Return on Total Capital | -1,104.038 |
| Return on Invested Capital | -393.484 |
VINC Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |